# Asana timeline entity: /record/asana.md id: ent_asana ## 2008 - 2008-01-01 | founded | 2008 | unverified | [clm_6922BE302C2B](/claim/clm_6922BE302C2B.md) ## 2018 - 2018-01-31 to 2019-01-31 | total_equity | -142,202,000 United States dollar | superseded | [clm_64033AC5E376](/claim/clm_64033AC5E376.md) ## 2019 - 2019-01-31 to 2019-10-31 | cash_and_equivalents | 23,778,000 United States dollar | superseded | [clm_3772AB7AD121](/claim/clm_3772AB7AD121.md) - 2019-01-31 to 2020-01-31 | net_income | -50,928,000 United States dollar | superseded | [clm_A8160C64AA61](/claim/clm_A8160C64AA61.md) - 2019-01-31 to 2020-01-31 | operating_income | -52,013,000 United States dollar | superseded | [clm_DF46BDDC2495](/claim/clm_DF46BDDC2495.md) - 2019-01-31 to 2020-01-31 | research_and_development | 42,585,000 United States dollar | superseded | [clm_445EC3A5132B](/claim/clm_445EC3A5132B.md) - 2019-01-31 to 2020-01-31 | revenue | 76,770,000 United States dollar | superseded | [clm_366392176019](/claim/clm_366392176019.md) - 2019-01-31 to 2019-07-31 | total_equity | -181,011,000 United States dollar | superseded | [clm_E726ED4546E9](/claim/clm_E726ED4546E9.md) - 2019-07-31 to 2019-10-31 | total_equity | -205,473,000 United States dollar | superseded | [clm_184F89F4F0D8](/claim/clm_184F89F4F0D8.md) - 2019-10-31 to 2020-01-31 | cash_and_equivalents | 14,539,000 United States dollar | superseded | [clm_0FBEC73FA560](/claim/clm_0FBEC73FA560.md) - 2019-10-31 to 2020-04-30 | quarterly_net_income | -62,803,000 United States dollar | superseded | [clm_A7B2C3F61830](/claim/clm_A7B2C3F61830.md) - 2019-10-31 to 2020-04-30 | quarterly_operating_income | -63,085,000 United States dollar | superseded | [clm_26B4960FAD44](/claim/clm_26B4960FAD44.md) - 2019-10-31 to 2020-04-30 | quarterly_research_and_development | 39,712,000 United States dollar | superseded | [clm_1C3A48D85D80](/claim/clm_1C3A48D85D80.md) - 2019-10-31 to 2020-04-30 | quarterly_revenue | 38,079,000 United States dollar | superseded | [clm_41C9044A52FB](/claim/clm_41C9044A52FB.md) - 2019-10-31 to 2020-01-31 | total_equity | -222,384,000 United States dollar | superseded | [clm_6AC58A82BADE](/claim/clm_6AC58A82BADE.md) ## 2020 - 2020-01-31 to 2020-04-30 | cash_and_equivalents | 306,020,000 United States dollar | superseded | [clm_9CDBA5A37173](/claim/clm_9CDBA5A37173.md) - 2020-01-31 to 2021-01-31 | net_income | -118,589,000 United States dollar | superseded | [clm_A83CC1863FF1](/claim/clm_A83CC1863FF1.md) - 2020-01-31 to 2021-01-31 | operating_income | -119,631,000 United States dollar | superseded | [clm_EC1E5D46AA74](/claim/clm_EC1E5D46AA74.md) - 2020-01-31 to 2021-01-31 | research_and_development | 89,675,000 United States dollar | superseded | [clm_5543DF541FE9](/claim/clm_5543DF541FE9.md) - 2020-01-31 to 2021-01-31 | revenue | 142,606,000 United States dollar | superseded | [clm_1B5D5D9521EB](/claim/clm_1B5D5D9521EB.md) - 2020-01-31 to 2020-10-31 | total_assets | 421,692,000 United States dollar | superseded | [clm_6506B2B2B3E2](/claim/clm_6506B2B2B3E2.md) - 2020-01-31 to 2020-04-30 | total_equity | -145,315,000 United States dollar | superseded | [clm_D7C6F75533CF](/claim/clm_D7C6F75533CF.md) - 2020-04-30 to 2020-07-31 | cash_and_equivalents | 315,609,000 United States dollar | superseded | [clm_3219F9FC2647](/claim/clm_3219F9FC2647.md) - 2020-04-30 to 2020-07-31 | quarterly_net_income | -35,845,000 United States dollar | superseded | [clm_CEFA01A82621](/claim/clm_CEFA01A82621.md) - 2020-04-30 to 2020-07-31 | quarterly_operating_income | -29,085,000 United States dollar | superseded | [clm_1FC913E6E6A1](/claim/clm_1FC913E6E6A1.md) - 2020-04-30 to 2020-07-31 | quarterly_research_and_development | 22,383,000 United States dollar | superseded | [clm_4098652B885B](/claim/clm_4098652B885B.md) - 2020-04-30 to 2020-07-31 | quarterly_revenue | 47,706,000 United States dollar | superseded | [clm_0FAF24CE13D5](/claim/clm_0FAF24CE13D5.md) - 2020-04-30 to 2020-07-31 | total_equity | -175,611,000 United States dollar | superseded | [clm_F92E8171E7D8](/claim/clm_F92E8171E7D8.md) - 2020-07-31 to 2020-10-31 | cash_and_equivalents | 449,519,000 United States dollar | superseded | [clm_57889A4D86EB](/claim/clm_57889A4D86EB.md) - 2020-07-31 to 2020-10-31 | quarterly_net_income | -41,066,000 United States dollar | superseded | [clm_CD745CA3C993](/claim/clm_CD745CA3C993.md) - 2020-07-31 to 2020-10-31 | quarterly_operating_income | -33,584,000 United States dollar | superseded | [clm_7028487FEFDC](/claim/clm_7028487FEFDC.md) - 2020-07-31 to 2020-10-31 | quarterly_research_and_development | 25,959,000 United States dollar | superseded | [clm_BD5903AE3B6C](/claim/clm_BD5903AE3B6C.md) - 2020-07-31 to 2020-10-31 | quarterly_revenue | 52,024,000 United States dollar | superseded | [clm_B387727CE689](/claim/clm_B387727CE689.md) - 2020-07-31 to 2020-10-31 | total_equity | -171,704,000 United States dollar | superseded | [clm_D7D2D9F79ACE](/claim/clm_D7D2D9F79ACE.md) - 2020-10-31 to 2021-01-31 | cash_and_equivalents | 297,425,000 United States dollar | superseded | [clm_8A532C655B6F](/claim/clm_8A532C655B6F.md) - 2020-10-31 to 2021-04-30 | quarterly_net_income | -73,289,000 United States dollar | superseded | [clm_A30B1C70A08C](/claim/clm_A30B1C70A08C.md) - 2020-10-31 to 2021-04-30 | quarterly_operating_income | -61,934,000 United States dollar | superseded | [clm_6DB289108B59](/claim/clm_6DB289108B59.md) - 2020-10-31 to 2021-04-30 | quarterly_research_and_development | 32,996,000 United States dollar | superseded | [clm_A2CB79BF4EE6](/claim/clm_A2CB79BF4EE6.md) - 2020-10-31 to 2021-04-30 | quarterly_revenue | 58,905,000 United States dollar | superseded | [clm_7E7671437D72](/claim/clm_7E7671437D72.md) - 2020-10-31 to 2021-01-31 | total_assets | 673,985,000 United States dollar | superseded | [clm_B46DF4BD6AF1](/claim/clm_B46DF4BD6AF1.md) - 2020-10-31 to 2021-01-31 | total_equity | 27,696,000 United States dollar | superseded | [clm_9E7D55659978](/claim/clm_9E7D55659978.md) ## 2021 - 2021-01-31 to 2021-04-30 | cash_and_equivalents | 259,878,000 United States dollar | superseded | [clm_254C8FA374E5](/claim/clm_254C8FA374E5.md) - 2021-01-31 to 2022-01-31 | net_income | -211,710,000 United States dollar | superseded | [clm_E2743917FB5B](/claim/clm_E2743917FB5B.md) - 2021-01-31 to 2022-01-31 | operating_income | -175,567,000 United States dollar | superseded | [clm_983995B5CCB4](/claim/clm_983995B5CCB4.md) - 2021-01-31 to 2022-01-31 | research_and_development | 121,139,000 United States dollar | superseded | [clm_3E47A4B88057](/claim/clm_3E47A4B88057.md) - 2021-01-31 to 2022-01-31 | revenue | 227,004,000 United States dollar | superseded | [clm_74466994AD90](/claim/clm_74466994AD90.md) - 2021-01-31 to 2021-04-30 | total_assets | 731,119,000 United States dollar | superseded | [clm_16863506BCFD](/claim/clm_16863506BCFD.md) - 2021-01-31 to 2021-04-30 | total_equity | -12,789,000 United States dollar | superseded | [clm_3BFC62454EC6](/claim/clm_3BFC62454EC6.md) - 2021-04-30 to 2021-07-31 | cash_and_equivalents | 263,933,000 United States dollar | superseded | [clm_09A322B053CA](/claim/clm_09A322B053CA.md) - 2021-04-30 to 2021-07-31 | quarterly_net_income | -60,658,000 United States dollar | superseded | [clm_30414E2B8C5B](/claim/clm_30414E2B8C5B.md) - 2021-04-30 to 2021-07-31 | quarterly_operating_income | -49,982,000 United States dollar | superseded | [clm_24953EAF7AB3](/claim/clm_24953EAF7AB3.md) - 2021-04-30 to 2021-07-31 | quarterly_research_and_development | 39,967,000 United States dollar | superseded | [clm_AE737902046D](/claim/clm_AE737902046D.md) - 2021-04-30 to 2021-07-31 | quarterly_revenue | 76,673,000 United States dollar | superseded | [clm_08D533E4886A](/claim/clm_08D533E4886A.md) - 2021-04-30 to 2021-07-31 | total_assets | 747,593,000 United States dollar | superseded | [clm_D187292D68EE](/claim/clm_D187292D68EE.md) - 2021-04-30 to 2021-07-31 | total_equity | -47,699,000 United States dollar | superseded | [clm_A95C7EDE8E98](/claim/clm_A95C7EDE8E98.md) - 2021-07-31 to 2021-10-31 | cash_and_equivalents | 270,315,000 United States dollar | superseded | [clm_50B0F31E8F4D](/claim/clm_50B0F31E8F4D.md) - 2021-07-31 to 2021-10-31 | quarterly_net_income | -68,355,000 United States dollar | superseded | [clm_D998AB110F1A](/claim/clm_D998AB110F1A.md) - 2021-07-31 to 2021-10-31 | quarterly_operating_income | -60,051,000 United States dollar | superseded | [clm_337D8B832566](/claim/clm_337D8B832566.md) - 2021-07-31 to 2021-10-31 | quarterly_research_and_development | 48,454,000 United States dollar | superseded | [clm_D3FBC6BEFE39](/claim/clm_D3FBC6BEFE39.md) - 2021-07-31 to 2021-10-31 | quarterly_revenue | 89,478,000 United States dollar | superseded | [clm_6AFAACE627DE](/claim/clm_6AFAACE627DE.md) - 2021-07-31 to 2021-10-31 | total_assets | 735,508,000 United States dollar | superseded | [clm_4D1390AF0CD2](/claim/clm_4D1390AF0CD2.md) - 2021-07-31 to 2021-10-31 | total_equity | 279,264,000 United States dollar | superseded | [clm_C0E94F3F4983](/claim/clm_C0E94F3F4983.md) - 2021-10-31 to 2022-01-31 | cash_and_equivalents | 271,818,000 United States dollar | superseded | [clm_4EC01EC0E25D](/claim/clm_4EC01EC0E25D.md) - 2021-10-31 to 2022-04-30 | quarterly_net_income | -69,280,000 United States dollar | superseded | [clm_0DF2414F68AF](/claim/clm_0DF2414F68AF.md) - 2021-10-31 to 2022-04-30 | quarterly_operating_income | -68,088,000 United States dollar | superseded | [clm_AFA1B1FBE452](/claim/clm_AFA1B1FBE452.md) - 2021-10-31 to 2022-04-30 | quarterly_research_and_development | 53,788,000 United States dollar | superseded | [clm_27D6E6800453](/claim/clm_27D6E6800453.md) - 2021-10-31 to 2022-04-30 | quarterly_revenue | 100,337,000 United States dollar | superseded | [clm_3462BDE5757D](/claim/clm_3462BDE5757D.md) - 2021-10-31 to 2022-01-31 | total_assets | 719,781,000 United States dollar | superseded | [clm_318CA8292187](/claim/clm_318CA8292187.md) - 2021-10-31 to 2022-01-31 | total_equity | 247,461,000 United States dollar | superseded | [clm_7DC6957F1192](/claim/clm_7DC6957F1192.md) ## 2022 - 2022-01-31 to 2022-04-30 | cash_and_equivalents | 240,403,000 United States dollar | superseded | [clm_CD877041D94D](/claim/clm_CD877041D94D.md) - 2022-01-31 to 2023-01-31 | net_income | -288,342,000 United States dollar | superseded | [clm_321DEFAE3621](/claim/clm_321DEFAE3621.md) - 2022-01-31 to 2023-01-31 | operating_income | -265,184,000 United States dollar | superseded | [clm_EC37D6D939EA](/claim/clm_EC37D6D939EA.md) - 2022-01-31 to 2023-01-31 | research_and_development | 203,124,000 United States dollar | superseded | [clm_A89A9E9F7B93](/claim/clm_A89A9E9F7B93.md) - 2022-01-31 to 2023-01-31 | revenue | 378,437,000 United States dollar | superseded | [clm_78D3FEF4FA9E](/claim/clm_78D3FEF4FA9E.md) - 2022-01-31 to 2022-04-30 | total_assets | 707,035,000 United States dollar | superseded | [clm_148B16C0913A](/claim/clm_148B16C0913A.md) - 2022-01-31 to 2022-04-30 | total_equity | 203,840,000 United States dollar | superseded | [clm_964534E07D10](/claim/clm_964534E07D10.md) - 2022-04-30 to 2022-07-31 | cash_and_equivalents | 197,328,000 United States dollar | superseded | [clm_96DE6AB3FE27](/claim/clm_96DE6AB3FE27.md) - 2022-04-30 to 2022-07-31 | quarterly_net_income | -98,868,000 United States dollar | superseded | [clm_37F9F0F0DA8B](/claim/clm_37F9F0F0DA8B.md) - 2022-04-30 to 2022-07-31 | quarterly_operating_income | -96,232,000 United States dollar | superseded | [clm_5359E4B73A6D](/claim/clm_5359E4B73A6D.md) - 2022-04-30 to 2022-07-31 | quarterly_research_and_development | 65,205,000 United States dollar | superseded | [clm_92446EC9816D](/claim/clm_92446EC9816D.md) - 2022-04-30 to 2022-07-31 | quarterly_revenue | 120,646,000 United States dollar | superseded | [clm_4485FD324ED9](/claim/clm_4485FD324ED9.md) - 2022-04-30 to 2022-07-31 | total_assets | 691,071,000 United States dollar | superseded | [clm_967A2BB36A27](/claim/clm_967A2BB36A27.md) - 2022-04-30 to 2022-07-31 | total_equity | 155,973,000 United States dollar | superseded | [clm_90181A3DC351](/claim/clm_90181A3DC351.md) - 2022-07-31 to 2022-10-31 | cash_and_equivalents | 148,458,000 United States dollar | superseded | [clm_B652E3164AD3](/claim/clm_B652E3164AD3.md) - 2022-07-31 to 2022-10-31 | quarterly_net_income | -112,969,000 United States dollar | superseded | [clm_44CB9D5320F3](/claim/clm_44CB9D5320F3.md) - 2022-07-31 to 2022-10-31 | quarterly_operating_income | -111,272,000 United States dollar | superseded | [clm_E93B1DACB1E6](/claim/clm_E93B1DACB1E6.md) - 2022-07-31 to 2022-10-31 | quarterly_research_and_development | 75,233,000 United States dollar | superseded | [clm_7CF1A2DCF1A1](/claim/clm_7CF1A2DCF1A1.md) - 2022-07-31 to 2022-10-31 | quarterly_revenue | 134,896,000 United States dollar | superseded | [clm_AC47D6FCE2AD](/claim/clm_AC47D6FCE2AD.md) - 2022-07-31 to 2022-10-31 | total_assets | 639,649,000 United States dollar | superseded | [clm_FEE9AC9E7FAA](/claim/clm_FEE9AC9E7FAA.md) - 2022-07-31 to 2022-10-31 | total_equity | 92,121,000 United States dollar | superseded | [clm_814A1F6CC651](/claim/clm_814A1F6CC651.md) - 2022-10-31 to 2023-01-31 | cash_and_equivalents | 509,091,000 United States dollar | superseded | [clm_A1C1FF01FDF9](/claim/clm_A1C1FF01FDF9.md) - 2022-10-31 to 2023-04-30 | quarterly_net_income | -100,905,000 United States dollar | superseded | [clm_F22C7F906FD0](/claim/clm_F22C7F906FD0.md) - 2022-10-31 to 2023-04-30 | quarterly_operating_income | -101,108,000 United States dollar | superseded | [clm_A5D7AEBFBFEB](/claim/clm_A5D7AEBFBFEB.md) - 2022-10-31 to 2023-04-30 | quarterly_research_and_development | 75,509,000 United States dollar | superseded | [clm_16D19D4D5181](/claim/clm_16D19D4D5181.md) - 2022-10-31 to 2023-04-30 | quarterly_revenue | 141,439,000 United States dollar | superseded | [clm_B4A968C07EE1](/claim/clm_B4A968C07EE1.md) - 2022-10-31 to 2023-01-31 | total_assets | 953,008,000 United States dollar | superseded | [clm_E0EE3DC58B49](/claim/clm_E0EE3DC58B49.md) - 2022-10-31 to 2023-01-31 | total_equity | 394,969,000 United States dollar | superseded | [clm_A90A9F77B96B](/claim/clm_A90A9F77B96B.md) ## 2023 - 2023-01-31 to 2023-04-30 | cash_and_equivalents | 526,563,000 United States dollar | superseded | [clm_6B49AE3BC77E](/claim/clm_6B49AE3BC77E.md) - 2023-01-31 to 2024-01-31 | net_income | -407,768,000 United States dollar | superseded | [clm_10288F0C0280](/claim/clm_10288F0C0280.md) - 2023-01-31 to 2024-01-31 | operating_income | -407,826,000 United States dollar | superseded | [clm_5D86510BAF98](/claim/clm_5D86510BAF98.md) - 2023-01-31 to 2024-01-31 | research_and_development | 297,209,000 United States dollar | superseded | [clm_BEF3C6AD956F](/claim/clm_BEF3C6AD956F.md) - 2023-01-31 to 2024-01-31 | revenue | 547,212,000 United States dollar | superseded | [clm_8804A5AF5039](/claim/clm_8804A5AF5039.md) - 2023-01-31 to 2023-04-30 | total_assets | 954,963,000 United States dollar | superseded | [clm_F7FBAB18C440](/claim/clm_F7FBAB18C440.md) - 2023-01-31 to 2023-04-30 | total_equity | 356,574,000 United States dollar | superseded | [clm_C7E0DDAAB0EE](/claim/clm_C7E0DDAAB0EE.md) - 2023-04-30 to 2023-07-31 | cash_and_equivalents | 382,234,000 United States dollar | superseded | [clm_4938AE5472C3](/claim/clm_4938AE5472C3.md) - 2023-04-30 to 2023-07-31 | quarterly_net_income | -61,468,000 United States dollar | superseded | [clm_8F44CFF1B010](/claim/clm_8F44CFF1B010.md) - 2023-04-30 to 2023-07-31 | quarterly_operating_income | -65,245,000 United States dollar | superseded | [clm_9CF1B1E20A84](/claim/clm_9CF1B1E20A84.md) - 2023-04-30 to 2023-07-31 | quarterly_research_and_development | 76,316,000 United States dollar | superseded | [clm_30F2654C5EF5](/claim/clm_30F2654C5EF5.md) - 2023-04-30 to 2023-07-31 | quarterly_revenue | 152,411,000 United States dollar | superseded | [clm_72979B5B2CBB](/claim/clm_72979B5B2CBB.md) - 2023-04-30 to 2023-07-31 | total_assets | 984,287,000 United States dollar | superseded | [clm_10FEB79686B5](/claim/clm_10FEB79686B5.md) - 2023-04-30 to 2023-07-31 | total_equity | 348,085,000 United States dollar | superseded | [clm_9CABD629A4B8](/claim/clm_9CABD629A4B8.md) - 2023-07-31 to 2023-10-31 | cash_and_equivalents | 413,697,000 United States dollar | superseded | [clm_52CE4009A5D9](/claim/clm_52CE4009A5D9.md) - 2023-07-31 to 2023-10-31 | quarterly_net_income | -71,414,000 United States dollar | superseded | [clm_2E1B481D0E74](/claim/clm_2E1B481D0E74.md) - 2023-07-31 to 2023-10-31 | quarterly_operating_income | -73,383,000 United States dollar | superseded | [clm_3257AEEF4C59](/claim/clm_3257AEEF4C59.md) - 2023-07-31 to 2023-10-31 | quarterly_research_and_development | 84,371,000 United States dollar | superseded | [clm_C37726927C53](/claim/clm_C37726927C53.md) - 2023-07-31 to 2023-10-31 | quarterly_revenue | 162,455,000 United States dollar | superseded | [clm_EB76FB38B71C](/claim/clm_EB76FB38B71C.md) - 2023-07-31 to 2023-10-31 | total_assets | 956,407,000 United States dollar | superseded | [clm_3A4AA350FBBE](/claim/clm_3A4AA350FBBE.md) - 2023-07-31 to 2023-10-31 | total_equity | 334,253,000 United States dollar | superseded | [clm_A738D8EE76AD](/claim/clm_A738D8EE76AD.md) - 2023-10-31 to 2024-01-31 | cash_and_equivalents | 268,314,000 United States dollar | superseded | [clm_F984AC227628](/claim/clm_F984AC227628.md) - 2023-10-31 to 2024-04-30 | quarterly_net_income | -61,750,000 United States dollar | superseded | [clm_6038DE97AD6B](/claim/clm_6038DE97AD6B.md) - 2023-10-31 to 2024-04-30 | quarterly_operating_income | -63,421,000 United States dollar | superseded | [clm_28721BC3A7F5](/claim/clm_28721BC3A7F5.md) - 2023-10-31 to 2024-04-30 | quarterly_research_and_development | 81,028,000 United States dollar | superseded | [clm_3E888CE8EE82](/claim/clm_3E888CE8EE82.md) - 2023-10-31 to 2024-04-30 | quarterly_revenue | 166,503,000 United States dollar | superseded | [clm_36A0D0CB8836](/claim/clm_36A0D0CB8836.md) - 2023-10-31 to 2024-01-31 | total_assets | 947,680,000 United States dollar | superseded | [clm_0CB566582F90](/claim/clm_0CB566582F90.md) - 2023-10-31 to 2024-01-31 | total_equity | 332,169,000 United States dollar | superseded | [clm_7E8CA9FBFD73](/claim/clm_7E8CA9FBFD73.md) ## 2024 - 2024-01-31 to 2024-04-30 | cash_and_equivalents | 236,663,000 United States dollar | superseded | [clm_59331D88F73E](/claim/clm_59331D88F73E.md) - 2024-01-31 to 2025-01-31 | net_income | -257,030,000 United States dollar | superseded | [clm_420B133A7765](/claim/clm_420B133A7765.md) - 2024-01-31 to 2025-01-31 | operating_income | -269,997,000 United States dollar | superseded | [clm_4A55F7064A57](/claim/clm_4A55F7064A57.md) - 2024-01-31 to 2025-01-31 | research_and_development | 324,688,000 United States dollar | superseded | [clm_A61433DE5D48](/claim/clm_A61433DE5D48.md) - 2024-01-31 to 2025-01-31 | revenue | 652,504,000 United States dollar | superseded | [clm_6F28A23B22DD](/claim/clm_6F28A23B22DD.md) - 2024-01-31 to 2024-04-30 | total_assets | 961,960,000 United States dollar | superseded | [clm_A42CACBE4F21](/claim/clm_A42CACBE4F21.md) - 2024-01-31 to 2024-04-30 | total_equity | 326,396,000 United States dollar | superseded | [clm_FD6CA695F979](/claim/clm_FD6CA695F979.md) - 2024-04-30 to 2024-07-31 | cash_and_equivalents | 222,049,000 United States dollar | superseded | [clm_0160E825D596](/claim/clm_0160E825D596.md) - 2024-04-30 to 2024-07-31 | quarterly_net_income | -63,722,000 United States dollar | superseded | [clm_EAA8CB212F96](/claim/clm_EAA8CB212F96.md) - 2024-04-30 to 2024-07-31 | quarterly_operating_income | -66,169,000 United States dollar | superseded | [clm_7B0A1D600C76](/claim/clm_7B0A1D600C76.md) - 2024-04-30 to 2024-07-31 | quarterly_research_and_development | 82,791,000 United States dollar | superseded | [clm_FE2D404F601F](/claim/clm_FE2D404F601F.md) - 2024-04-30 to 2024-07-31 | quarterly_revenue | 172,448,000 United States dollar | superseded | [clm_3A65884C750E](/claim/clm_3A65884C750E.md) - 2024-04-30 to 2024-07-31 | total_assets | 978,168,000 United States dollar | superseded | [clm_E0E937FDF793](/claim/clm_E0E937FDF793.md) - 2024-04-30 to 2024-07-31 | total_equity | 319,897,000 United States dollar | superseded | [clm_567C2731203F](/claim/clm_567C2731203F.md) - 2024-07-31 to 2024-10-31 | cash_and_equivalents | 219,400,000 United States dollar | superseded | [clm_6DB3814DF1E3](/claim/clm_6DB3814DF1E3.md) - 2024-07-31 to 2024-10-31 | quarterly_net_income | -72,189,000 United States dollar | superseded | [clm_C0B08DDBD76E](/claim/clm_C0B08DDBD76E.md) - 2024-07-31 to 2024-10-31 | quarterly_operating_income | -76,797,000 United States dollar | superseded | [clm_1244E01C765A](/claim/clm_1244E01C765A.md) - 2024-07-31 to 2024-10-31 | quarterly_research_and_development | 91,151,000 United States dollar | superseded | [clm_FBAAA7D8190C](/claim/clm_FBAAA7D8190C.md) - 2024-07-31 to 2024-10-31 | quarterly_revenue | 179,212,000 United States dollar | superseded | [clm_6401B9DE5CE5](/claim/clm_6401B9DE5CE5.md) - 2024-07-31 to 2024-10-31 | total_assets | 945,376,000 United States dollar | superseded | [clm_0210BB289DE2](/claim/clm_0210BB289DE2.md) - 2024-07-31 to 2024-10-31 | total_equity | 291,917,000 United States dollar | superseded | [clm_593FF7F48166](/claim/clm_593FF7F48166.md) - 2024-09-11 to 2026-03-24 | cfo | Sonalee Parekh | superseded | [clm_3589B3C7BDDA](/claim/clm_3589B3C7BDDA.md) - 2024-10-31 to 2025-01-31 | cash_and_equivalents | 196,772,000 United States dollar | superseded | [clm_74901A242097](/claim/clm_74901A242097.md) - 2024-10-31 to 2025-04-30 | quarterly_net_income | -57,326,000 United States dollar | superseded | [clm_E480E8B855E0](/claim/clm_E480E8B855E0.md) - 2024-10-31 to 2025-04-30 | quarterly_operating_income | -60,180,000 United States dollar | superseded | [clm_A66B427B2796](/claim/clm_A66B427B2796.md) - 2024-10-31 to 2025-04-30 | quarterly_research_and_development | 83,286,000 United States dollar | superseded | [clm_8C9851B757D9](/claim/clm_8C9851B757D9.md) - 2024-10-31 to 2025-04-30 | quarterly_revenue | 183,882,000 United States dollar | superseded | [clm_03C17ACB461E](/claim/clm_03C17ACB461E.md) - 2024-10-31 to 2025-01-31 | total_assets | 874,156,000 United States dollar | superseded | [clm_90783A7B0EC0](/claim/clm_90783A7B0EC0.md) - 2024-10-31 to 2025-01-31 | total_equity | 239,270,000 United States dollar | superseded | [clm_1EA7830A0176](/claim/clm_1EA7830A0176.md) ## 2025 - 2025-01-31 to 2025-04-30 | cash_and_equivalents | 184,728,000 United States dollar | superseded | [clm_18303395C783](/claim/clm_18303395C783.md) - 2025-01-31 to 2026-01-31 | net_income | -255,536,000 United States dollar | superseded | [clm_460AA82BA62D](/claim/clm_460AA82BA62D.md) - 2025-01-31 to 2026-01-31 | operating_income | -266,735,000 United States dollar | superseded | [clm_B47055CAE7DF](/claim/clm_B47055CAE7DF.md) - 2025-01-31 to 2026-01-31 | research_and_development | 341,467,000 United States dollar | superseded | [clm_6113C8EEF71E](/claim/clm_6113C8EEF71E.md) - 2025-01-31 to 2026-01-31 | revenue | 723,876,000 United States dollar | superseded | [clm_F2FC64F8B131](/claim/clm_F2FC64F8B131.md) - 2025-01-31 to 2025-04-30 | total_assets | 891,415,000 United States dollar | superseded | [clm_AA9760752B82](/claim/clm_AA9760752B82.md) - 2025-01-31 to 2025-04-30 | total_equity | 227,523,000 United States dollar | superseded | [clm_0D2B2084D8B9](/claim/clm_0D2B2084D8B9.md) - 2025-04-30 to 2025-07-31 | cash_and_equivalents | 193,791,000 United States dollar | superseded | [clm_86A311CEE276](/claim/clm_86A311CEE276.md) - 2025-04-30 to 2025-07-31 | quarterly_net_income | -40,018,000 United States dollar | superseded | [clm_E52910D80F91](/claim/clm_E52910D80F91.md) - 2025-04-30 to 2025-07-31 | quarterly_operating_income | -43,904,000 United States dollar | superseded | [clm_59E8BC204696](/claim/clm_59E8BC204696.md) - 2025-04-30 to 2025-07-31 | quarterly_research_and_development | 75,127,000 United States dollar | superseded | [clm_622CCA6823FF](/claim/clm_622CCA6823FF.md) - 2025-04-30 to 2025-07-31 | quarterly_revenue | 187,267,000 United States dollar | superseded | [clm_8B52BDC7EEB2](/claim/clm_8B52BDC7EEB2.md) - 2025-04-30 to 2025-07-31 | total_assets | 877,133,000 United States dollar | superseded | [clm_74C669F90787](/claim/clm_74C669F90787.md) - 2025-04-30 to 2025-07-31 | total_equity | 236,304,000 United States dollar | superseded | [clm_4476C5B190A1](/claim/clm_4476C5B190A1.md) - 2025-07-21 | ceo | Daniel Rogers | valid | [clm_2D083951E3B7](/claim/clm_2D083951E3B7.md) - 2025-07-31 to 2025-10-31 | cash_and_equivalents | 184,146,000 United States dollar | superseded | [clm_C2DD07078D8A](/claim/clm_C2DD07078D8A.md) - 2025-07-31 to 2025-10-31 | quarterly_net_income | -48,360,000 United States dollar | superseded | [clm_1A393F56EC82](/claim/clm_1A393F56EC82.md) - 2025-07-31 to 2025-10-31 | quarterly_operating_income | -49,456,000 United States dollar | superseded | [clm_8BA15D000367](/claim/clm_8BA15D000367.md) - 2025-07-31 to 2025-10-31 | quarterly_research_and_development | 79,376,000 United States dollar | superseded | [clm_3E86266E9A5F](/claim/clm_3E86266E9A5F.md) - 2025-07-31 to 2025-10-31 | quarterly_revenue | 196,936,000 United States dollar | superseded | [clm_2107EE74E8B8](/claim/clm_2107EE74E8B8.md) - 2025-07-31 to 2025-10-31 | total_assets | 883,157,000 United States dollar | superseded | [clm_1C8BC5E1BFB3](/claim/clm_1C8BC5E1BFB3.md) - 2025-07-31 to 2025-10-31 | total_equity | 224,556,000 United States dollar | superseded | [clm_550C83FFF291](/claim/clm_550C83FFF291.md) - 2025-10-31 to 2026-01-31 | cash_and_equivalents | 183,470,000 United States dollar | superseded | [clm_1935A29761C6](/claim/clm_1935A29761C6.md) - 2025-10-31 to 2026-04-30 | quarterly_net_income | -68,433,000 United States dollar | superseded | [clm_45A982855580](/claim/clm_45A982855580.md) - 2025-10-31 to 2026-04-30 | quarterly_operating_income | -69,986,000 United States dollar | superseded | [clm_063C9E6D26B4](/claim/clm_063C9E6D26B4.md) - 2025-10-31 to 2026-04-30 | quarterly_research_and_development | 73,813,000 United States dollar | superseded | [clm_1FB8CA89D26D](/claim/clm_1FB8CA89D26D.md) - 2025-10-31 to 2026-04-30 | quarterly_revenue | 201,033,000 United States dollar | superseded | [clm_4EEC96332254](/claim/clm_4EEC96332254.md) - 2025-10-31 to 2026-01-31 | total_assets | 840,430,000 United States dollar | superseded | [clm_C19D47BA2D7A](/claim/clm_C19D47BA2D7A.md) - 2025-10-31 to 2026-01-31 | total_equity | 188,362,000 United States dollar | superseded | [clm_C66AE1482AEF](/claim/clm_C66AE1482AEF.md) ## 2026 - 2026-01-31 to 2026-04-30 | cash_and_equivalents | 199,835,000 United States dollar | superseded | [clm_2859F4EB9EA3](/claim/clm_2859F4EB9EA3.md) - 2026-01-31 | net_income | -189,024,000 United States dollar | valid | [clm_0AC381AF4C6C](/claim/clm_0AC381AF4C6C.md) - 2026-01-31 | operating_income | -197,331,000 United States dollar | valid | [clm_5C05855E7660](/claim/clm_5C05855E7660.md) - 2026-01-31 | research_and_development | 301,496,000 United States dollar | valid | [clm_BD72F6E30FA9](/claim/clm_BD72F6E30FA9.md) - 2026-01-31 | revenue | 790,806,000 United States dollar | valid | [clm_D76563BF8002](/claim/clm_D76563BF8002.md) - 2026-01-31 to 2026-04-30 | total_assets | 844,088,000 United States dollar | superseded | [clm_8D7B59839DE1](/claim/clm_8D7B59839DE1.md) - 2026-01-31 to 2026-04-30 | total_equity | 154,117,000 United States dollar | superseded | [clm_D105FFD13744](/claim/clm_D105FFD13744.md) - 2026-03-24 | cfo | Aziz Megji | valid | [clm_5DE2B1BEAB99](/claim/clm_5DE2B1BEAB99.md) - 2026-04-30 to 2026-07-31 | cash_and_equivalents | 193,656,000 United States dollar | superseded | [clm_452840EFCC84](/claim/clm_452840EFCC84.md) - 2026-04-30 to 2026-07-31 | quarterly_net_income | -14,405,000 United States dollar | superseded | [clm_43C6D8938854](/claim/clm_43C6D8938854.md) - 2026-04-30 to 2026-07-31 | quarterly_operating_income | -15,240,000 United States dollar | superseded | [clm_363277A4DE16](/claim/clm_363277A4DE16.md) - 2026-04-30 to 2026-07-31 | quarterly_research_and_development | 66,089,000 United States dollar | superseded | [clm_2F79656C8080](/claim/clm_2F79656C8080.md) - 2026-04-30 to 2026-07-31 | quarterly_revenue | 205,095,000 United States dollar | superseded | [clm_378DDC1B08DB](/claim/clm_378DDC1B08DB.md) - 2026-04-30 to 2026-07-31 | total_assets | 805,512,000 United States dollar | superseded | [clm_434936974FE5](/claim/clm_434936974FE5.md) - 2026-04-30 to 2026-07-31 | total_equity | 136,982,000 United States dollar | superseded | [clm_FB1A611EDBE2](/claim/clm_FB1A611EDBE2.md) - 2026-07-31 | cash_and_equivalents | 219,562,000 United States dollar | valid | [clm_429E44C585F9](/claim/clm_429E44C585F9.md) - 2026-07-31 | quarterly_net_income | -39,189,000 United States dollar | valid | [clm_7D0D7A2BBCA7](/claim/clm_7D0D7A2BBCA7.md) - 2026-07-31 | quarterly_operating_income | -41,219,000 United States dollar | valid | [clm_F6A887BF7E3D](/claim/clm_F6A887BF7E3D.md) - 2026-07-31 | quarterly_research_and_development | 81,728,000 United States dollar | valid | [clm_167117BF5B57](/claim/clm_167117BF5B57.md) - 2026-07-31 | quarterly_revenue | 216,429,000 United States dollar | valid | [clm_6CEC19065B4B](/claim/clm_6CEC19065B4B.md) - 2026-07-31 | total_assets | 816,149,000 United States dollar | valid | [clm_370543C3060E](/claim/clm_370543C3060E.md) - 2026-07-31 | total_equity | 104,323,000 United States dollar | valid | [clm_10449258069B](/claim/clm_10449258069B.md) - 2026-09-25 | chair | Dan Rogers | valid | [clm_30A2B04BAC97](/claim/clm_30A2B04BAC97.md) ## undated - undated | cik | 0001477720 | valid | [clm_43FDFA6AFF72](/claim/clm_43FDFA6AFF72.md) - undated | fiscal_year_end | 01-31 | valid | [clm_57DE746D1537](/claim/clm_57DE746D1537.md) - undated | headquarters | San Francisco | valid | [clm_330A4395F4E2](/claim/clm_330A4395F4E2.md) - undated | listed_on | NYSE | valid | [clm_F384DB109EE0](/claim/clm_F384DB109EE0.md) - undated | registrant_name | Asana, Inc. | valid | [clm_BFDB61859780](/claim/clm_BFDB61859780.md) - undated | sic_industry | Services-Prepackaged Software (7372) | valid | [clm_9508638743A2](/claim/clm_9508638743A2.md) - undated | state_of_incorporation | DE | valid | [clm_DBB945BE2951](/claim/clm_DBB945BE2951.md) - undated | ticker | ASAN | valid | [clm_35F815E920E8](/claim/clm_35F815E920E8.md) --- AsOf is a temporal fact ledger: a structured, dated, sourced record of what is true and what changed, built for AI retrieval.